TRDA News and Press, Entrada Therapeutics Inc. From 08/29/23

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company...

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the app...

2023-08-08 10:17:25 ET Entrada Therapeutics press release ( NASDAQ: TRDA ): Q2 GAAP EPS of -$0.78. Revenue of $18.2M. For further details see: Entrada Therapeutics GAAP EPS of -$0.78, revenue of $18.2M

– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 – – $377 million in cash, cash equivalents and marketable securities as of June 30, 2023 – – Cash runway through 2025 – ...

2023-08-03 18:39:00 ET Summary Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly $600mn and received a major deal with Vertex. Precl...

– First participant is expected to be dosed in September 2023 with data anticipated in the second half of 2024 – – Cash runway extended through the end of 2025 – BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: T...

2023-06-26 12:52:19 ET Gainers: Benitec Biopharma ( BNTC ) +76% . MoonLake Immunotherapeutics ( MLTX ) +68% . Paltalk ( PALT ) +27% . Whole Earth Brands ( FREE ) +26% . Shengfeng Development Limited ( SFWL ) +26% . Belite Bio...

BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dip...

2023-05-12 18:04:15 ET Summary Entrada Therapeutics, Inc., is a biotechnology developer of endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. After the results of the first quarter of 2023, the shares are still somewhat subdued, unfairly, b...

2023-05-10 13:51:57 ET Entrada Therapeutics press release ( NASDAQ: TRDA ): Q1 GAAP EPS of -$0.21. Revenue of $25.26M. For further details see: Entrada Therapeutics GAAP EPS of -$0.21, revenue of $25.26M